Sunshine Biopharma's Nora Pharma receives Health Canada approval for NIOPEG®, a pegfilgrastim biosimilar.
Sunshine Biopharma's Nora Pharma subsidiary receives Health Canada approval for NIOPEG®, a biosimilar pegylated form of filgrastim (pegfilgrastim) comparable to Neulasta®. The market size of pegfilgrastim in Canada is approximately $88M. NIOPEG®, a long-acting r-HuG-CSF, is indicated to decrease infection incidence in non-myeloid malignancy patients with febrile neutropenia.
April 19, 2024
4 Articles